<DOC>
	<DOCNO>NCT00285675</DOCNO>
	<brief_summary>The purpose study monitor safety continue DN-101 docetaxel treatment subject previously enrol DN101-002 ( ASCENT ) DN101-004 ( NSCLC ) Studies .</brief_summary>
	<brief_title>Study DN-101 ( Calcitriol ) Docetaxel Subjects Previously Enrolled Studies DN101-002 DN101-004</brief_title>
	<detailed_description>This multicenter , open-label trial DN-101 docetaxel combination therapy monitor safety ongoing DN-101 docetaxel treatment subject previously enrol DN101-002 DN101-004 study . For subject enrol DN101-002 study , subject randomize DN-101 treatment arm currently receive study drug ( include subject study suspension / holiday ) include current study . For subject enrol DN101-004 study , subject receive study treatment include . Safety assess throughout study . Safety evaluation consist modified physical exam ( vital sign weight ) laboratory assessment . Modified physical exam perform begin treatment cycle . Docetaxel-related laboratory assessment perform per standard care note label . DN-101-related laboratory assessment serum calcium serum creatinine perform begin treatment cycle . Clinically significant abnormal laboratory value report adverse event .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Prior participation DN101002 DN101004 study , subject receive least one dose DN101 Able willing give write informed consent Disease progression unacceptable toxicity previously enrol DN101002 DN101004 study Prior investigational therapy DN101 within 30 day enrollment Known hypersensitivity calcitriol Pregnancy ( woman childbearing potential ) Greater 90 day elapse termination DN101002 DN101004 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Calcitriol , DN-101 , Androgen Independent Prostate Cancer ( AIPC ) , Prostate Cancer , Non Small Cell Lung Cancer ( NSCLC )</keyword>
</DOC>